Condition: Monoclonal Gammopathy of Renal Significance · Sponsor: Peking University People's Hospital
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
This description comes directly from the study's public registry record.
Jin Lu · 86-13311491805 · jin1lu@sina.com
Yang Liu · 86-13716926210 · pkuphliuyang@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06418477